Funding for this research was provided by:
A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
Dept. of internal medicine, University Hospital of Copenhagen Amager
The Clinical Research Center, University Hospital of Copenhagen Hvidovre
The Bispebjerg Hospital Research Foundation
Text and Data Mining valid from 2019-05-31
Received: 25 February 2019
Accepted: 17 May 2019
First Online: 31 May 2019
Ethics approval and consent to participate
: The study has been approved by the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark informed consent was obtained from all participants.
: Not applicable.
: CA: Advisory board and lecture fees: Novo Nordisk. PK: none. AJ: none. LRP: share owner: Novo Nordisk. OWN: funding of educational and research tasks from ResMed and participated on advisory boards for Novartis. OPK: none. MF: none. JJH: none. SM: Advisory boards: AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Eli Lilly; Intarcia Therapeutics; Johnson & Johnson; Merck Sharp & Dohme; Novartis; Novo Nordisk; Sanofi Aventis. Lecture fees: AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Eli Lilly; Merck Sharp & Dohme; Novartis; Novo Nordisk; Sanofi Aventis. Research Grant Recipient: Novo Nordisk. AS: none. SBH: has received funding of educational and research tasks from Novo Nordisk, Abbott, Eli Lilly, Pfizer, Boehringer Ingelheim, Bristol-Meyers Squibb, and Merck Sharp & Dohme.